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Abstract
Background: One of the main problems in B cell lymphoma treatment is severe adverse effects and low
therapeutic efficacy resulting from systemic chemotherapy. A pH-sensitive controlled drug release system based
on mesoporous silica nanoparticles was constructed for targeted drug delivery to tumor cells to reduce systemic
toxicity and improve the therapeutic efficacy.
Methods: In this study, the doxorubicin (DOX) was filled into the mesopores of the functional MSNs (DMSNs).
Furthermore, rituximab was introduced as the targeted motif of functional DMSNs using an avidin-biotin bridging
method to evaluate the targetability to tumor cells. Then, the cell viability and apoptosis efficiency after treatment
with rituximab-conjugated DMSNs (RDMSNs) were estimated by using CCK-8 assay and flow cytometry, respectively.
Additionally, the research in vivo was performed to evaluate the enhanced antitumor efficacy and the minimal toxic
side effects of RDMSNs. Also, TUNEL staining assay was employed to explore the mechanism of antitumor effects of
RDMSNs.
Results: This targeted drug delivery system exhibited low premature drug release at a physiological pH and
efficient pH-responsive intracellular release under weakly acidic conditions. The in vitro tests confirmed that
targeted RDMSNs could selectively adhere to the surface of lymphoma B cells via specific binding with the
CD20 antigen and be internalized into CD20 positive Raji cells but few CD20 negative Jurkat cells, which leads
to increased cytotoxicity and apoptosis of the DOX in Raji cells due to the release of the entrapped DOX with
high efficiency in the slightly acidic intracellular microenvironment. Furthermore, the in vivo investigations
confirmed that RDMSNs could efficiently deliver DOX to lymphoma B cells by pH stimuli, thus inducing cell
apoptosis and inhibiting tumor growth, while with minimal toxic side effects.
Conclusions: This targeted and pH-sensitive controlled drug delivery system has the potential for promising
application to enhance the therapeutic index and reduce the side effects of B cell lymphoma therapy.
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Background
Lymphoma remains one of the primary causes of cancer
mortality globally. Systemic chemotherapy is an indispens-
able treatment for many types of lymphoma. Rituximab, a
chimeric monoclonal antibody that can specifically inter-
act with the CD20 antigen [1], combined with doxorubicin
(DOX) have been extensively used for improving the prog-
nosis of B cell lymphoma over the past few decades [2].
Although these treatments have favorable therapeutic
effects in most cases, significant adverse effects may occur
due to premature drug release prior to reaching the
targeted sites and nonspecific biodistribution in normal
tissues [3]. Therefore, exploring new therapeutic strategies
is necessary for preventing drugs from prematurely releas-
ing during blood circulation, controlling drug nonspecific
biodistribution, reducing off-target toxicity, and improving
the therapeutic efficacy.
Nanoparticles have been reported to serve as drug
delivery carriers in the nanomedicine field. Recently,
mesoporous silica nanoparticles (MSNs) have attracted
much attention due to their favorable properties includ-
ing good biocompatibility, high stability, tunable pore
diameter, unique porous structure, large loading cap-
acity, and easy surface functionalization [4–9]. The
ordered pore network of these MSNs can effectively load
drug within the channels. Additionally, MSNs can also
be designed to trigger the release of a loaded drug in
response to either external or internal stimuli, such as
temperature [10, 11], light [12, 13], redox reactions
[14–16], enzymes [17, 18], pH value [19, 20], and bio-
molecules [21, 22]. Among these stimuli, pH-responsive
drug release mechanisms are considered as a facile and
convenient method for controlled drug release using a
low pH signal, because endosomes and lysosomes
formed in cells after internalization of drug delivery car-
riers are relatively more acidic with a pH of 4.5–5.5 [23].
Therefore, various types of pH-responsive drug delivery
carriers based on MSNs have been developed to control
drug release via a pH signal in endosomes and lyso-
somes. However, the use of only single pH-responsive
MSNs that are based on passive targetability via en-
hanced permeability and retention effects for drug
delivery results in facile internalization by normal cells
through an unspecific uptake method. Therefore, several
studies have reported that the external surface of MSNs
can be modified with tumor-specific ligands to improve
the active targetability by increasing the affinity between
the receptor and the ligand. Various types of targeted li-
gands, such as folate [24], peptides [25], glycyrrhetinic
acid [26], hyaluronic acid [27], mannose [28], arginine-
glycine-aspartate [29], DNA aptamer [30], and lactobionic
acid [31], have been successfully conjugated to drug deliv-
ery carriers, leading to an enhanced anticancer drug
therapeutic index. At present, these ligands primarily
targeted solid tumors rather than lymphoma and were
rarely used in clinical applications for cancer molecular
targeting therapy due to unwanted immunogenicity.
Therefore, the development of intracellular pH-responsive
and active targeted drug-loaded MSNs is urgently needed
for minimizing the side effects and maximizing the thera-
peutic efficacy for lymphatic system tumors.
In our previous study, rituximab was conjugated onto
the surface of DOX - loaded microbubbles to improve
targetability to CD20 receptor-overexpressed Raji cells,
and rituximab conjugated and DOX-loaded micro-
bubbles combined with ultrasound increased the re-
lease of DOX, resulting in enhanced antitumor efficacy
[32]. In this study, the biocompatible poly (ethylene
glycol) (PEG), which is a hydrophilic protection layer,
can prevent functional MSNs from absorbing plasma
proteins and being recognized by the reticuloendothe-
lial system for clearance to allow for a prolonged blood
circulation lifetime [33, 34]. Then, the functional DOX
-loaded MSNs (DMSNs) were conjugated with the
PEG. Moreover, rituximab was employed as a targeted
ligand in the drug delivery system based on DMSNs.
Therefore, we supposed that an intracellular pH-
responsive and rituximab conjugated DOX-loaded MSNs
(RDMSNs) was constructed for B cell lymphoma therapy.
As mentioned above and envisioned in Scheme 1, in this
paper we aim to evaluate whether (a) it is possible to
design an intracellular pH-responsive and targeted drug
delivery system based on MSNs, (b) targeted drug delivery
system are able to selectively adhere to CD20 antigen
positive lymphoma B cells and (c) whether molecules
(i.e., DOX) can be selectively delivered to CD20 anti-
gen positive lymphoma B cells upon binding with
RDMSNs via the receptor-mediated endocytosis pathway
for improving the therapeutic index.
Methods
Materials
Mesoporous silica nanoparticles were purchased from
Anhui JingYe Nano Technology Co., Ltd. N-(trimethoxy-
silylpropyl) ethylenediamine triacetic acid was obtained
from J&K Scientific Ltd. Doxorubicin hydrochloride was
obtained from Shenzhen Wanle Pharmaceutical Co.,
Ltd. N-hydroxysuccinimide (NHS) was purchased from
Aladdin Industrial Corporation. Amine-Peg2000-Biotin,
the EZ-Link™ Sulfo-LC Biotinylation Kit and 1-ethyl-3-
(3-dimethylaminopropyl) carbodiimide hydrochloride
(EDC) were purchased from Thermo Fisher Scientific.
Dylight 488-Avidin was obtained from Wuhan Boster
Biological Engineering Co., Ltd. Rituximab was obtained
from Hoffmann-La Roche, Ltd. The DAPI (4,6-diamidino-
2-phenylindole) staining solution, Cell Counting Kit-8 and
the Annexin V-FITC/PI cell apoptosis detection kit were
purchased from Beyotime Biotechnology Co., Ltd.
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Preparation of carboxyl-modified MSNs
The surfaces of the obtained MSNs were modified with
carboxyl groups via hydrolyzation of N-(trimethoxysi-
lylpropyl) ethylenediamine triacetic acid. Briefly, the
MSNs (100 mg) were dispersed in anhydrous alcohol
(20 mL), and 0.1 mL of N-(trimethoxysilylpropyl) ethyl-
enediamine triacetic acid was added under continuous
stirring with a magnetic stirring apparatus at room
temperature for 24 h. Then, the resulting MSN-COOH
were collected by repeated centrifugation and rinsed
with a sterile PBS solution three times to remove the
reaction impurities.
Characterization
The morphological characterization of MSN-COOH
was performed using a scanning electron microscope
(SEM, Hitachi S-4800; Japan). The structures of MSN-
COOH were investigated using transmission electron
microscopy (TEM, Hitachi H-7600; Japan). The size
distribution and zeta potential of the MSN-COOH resus-
pended in PBS (pH 7.4) were measured using a Malvern
Zetasizer Nano ZS unit (Malvern Instruments, UK).
Fourier transform infrared (FTIR) analyses of MSN and
MSN-COOH were carried out on a Bruker Vertex 70
FTIR spectrometer. The pore size distributions and sur-
face areas of different MSNs materials were characterized
by Brunauer–Emmett–Teller (BET) and Barrett–Joyner–
Halenda (BJH) analyses (ASAP2020M, USA).
Drug loading
To load MSN-COOH with DOX, 5 mg of DOX hydro-
chloride was dissolved in 2 mL of PBS (pH 7.4), and
MSN-COOH was added to the solution. The mixture
was stirred on a magnetic stirring apparatus at room
temperature for 24 h under dark condition. The DOX
molecules can diffuse into the mesoporous channels
with carboxyl groups. The dispersion was detached by
centrifugation and washed with PBS to remove the
unloaded DOX. The DMSNs were resuspended in PBS.
The amount of supernatant DOX was estimated by
absorbance measurement at 488 nm using a TECAN
Infinite F50 Microplate Reader. Loading efficiency =
(initial weight of DOX - supernatant weight of DOX)/
weight of particles × 100%. Encapsulation efficiency =
(initial weight of DOX - supernatant weight of DOX) / initial
weight of DOX.
Preparation of targeting DMSNs
The resulting DMSNs were dissolved in PBS, and an
equimolar amount of EDC and NHS was added to the
solution. The carboxyl groups on the surface of the
DMSNs were activated for 1 h at room temperature in a
shaker. The supernatant was removed after the mixture
was centrifuged. The resulting precipitants were resus-
pended in PBS, and Amine-Peg2000-Biotin (5 mg) was
added to the solution. Next, the mixture was allowed to
react for 1 h at room temperature in a shaker to afford
Scheme 1 Self-assembly processes and structure of the RDMSNs and pH-responsive targeted drug delivery. Drug loading and rituximab conjugation
processes of RDMSNs, and illustration of the uptake and internalization of the RDMSNs via a CD20 antigen-mediated interaction and pH-triggered DOX
release in lysosome or endosome of the lymphoma B cells
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the biotinylated DMSNs. The biotinylated DMSNs were
incubated with DyLight 488-labeled avidin for 10 min.
The biotinylated DMSNs were collected by repeated
centrifugation and rinsed three times to remove the
redundant DyLight 488-labeled avidin. Then, rituximab
was biotinylated through the EZ-Link™ Sulfo- LC-
Biotinylation Kit according to the manufacturer’s
instructions. Finally, biotinylated rituximab was added to
the biotinylated DMSNs suspension and incubated for
10 min. The mixture was rinsed and purified to afford
the RDMSNs. Rituximab-conjugated MSNs (RMSNs)
were prepared using the same method but without DOX
hydrochloride.
The conjugation of rituximab on the surface of the
DMSNs was determined by measuring the absorbance of
the free DyLight 488-avidin solution and DyLight 488-
avidin conjugated DOX-loaded MSNs with a fluores-
cence spectrophotometer at a maximum excitation
wavelength of 493 nm and a maximum emission wave-
length of 518 nm. The binding efficiency of rituximab
on the DyLight 488-avidin conjugated DMSNs was
estimated as the ratio of the intensity of the DyLight
488-avidin conjugated DMSNs to the intensity of the
free DyLight 488-labeled avidin samples.
In vitro test of drug release
The DMSN and RDMSN samples were dissolved in
5 mL of PBS buffer (pH 5.5 or pH 7.4) or medium and
shaken at 37 °C under dark conditions. The samples
were centrifuged at certain intervals, and the amount of
released DOX in the supernatant was determined using
a TECAN Infinite F50 Microplate Reader.
Cell culture
Raji and Daudi (CD20-positive) cell lines and Jurkat
(CD20-negative) cell lines, which were purchased from
the Type Culture Collection of the Chinese Academy of
Sciences (Shanghai, People’s Republic of China), were
cultured in RPMI 1640 medium with 10% FBS (v/v) and
1% PS (v/v) at 37 °C under a humid atmosphere contain-
ing 5% CO2 at 37 °C. The cells used in the experiments
were in the logarithmic growth phase.
Cell recognition and cellular uptake of RDMSNs and
DMSNs
The Raji cells and Jurkat cells were seeded in a 12-well
plate (50,000 per well) and incubated with RDMSNs and
DMSNs with a DOX concentration of 0.5 μg/mL for 2 h
at 37 °C. After the medium was removed and the cells
were washed with PBS three times, flow cytometry
(FCM) was employed to quantify the mean fluorescence
intensity (MFI) of the RDMSNs and DMSNs internalized
into the cells based on DOX autofluorescence. Addition-
ally, the Raji cells and Jurkat cells were incubated with a
nuclear staining agent (DAPI) in NEST glass culture
dishes for 30 min followed by observation under a
confocal laser scanning microscope (CLSM FV1000;
Olympus, Japan) using a 100 × oil objective at excitation
wavelengths of 410 and 488 nm, respectively. Competi-
tive experiments were performed by pre-incubation of
Raji cells with excessive rituximab to block the CD20
antigen for 30 min followed by washing. Jurkat cells
were employed as a control.
Transmission electron microscopy was further employed
to observe cell uptake and intracellular distribution of the
nanoparticles. After the Raji cells were incubated with
RDMSN and DMSN for 24 h, these cells were collected by
repeated centrifugation and rinsed with PBS buffer. Then,
the Raji cells were immobilized with 2.5% glutaraldehyde
and observed using TEM.
Cell viability assay of RDMSNs and DMSNs
The cell viability was measured according to the instruc-
tions provided with the Cell Counting Kit-8 (CCK-8).
The Raji, Daudi and Jurkat cells were seeded in 24-well
plates (1 × 105 per well). The cells were incubated
with various concentrations of MSNs or rituximab-
conjugated MSNs (RMSNs) (i.e., 10, 20, 40, 80, or
100 μg/mL), Free DOX, RDMSNs and DMSNs contain-
ing various DOX concentrations (i.e., 0.1, 0.5, 1.0, 2.0, or
4.0 μg/mL). After incubation for 24 h, the cells were
washed with PBS buffer three times and placed in fresh
culture medium. Then, 10 μL of the CCK-8 solution
were added to each well followed by incubation for an
additional 4 h. The absorbance of the solution was
measured at 450 nm using a TECAN Infinite F50 Micro-
plate Reader.
Cell apoptosis assay of RDMSNs and DMSNs
The nuclear morphological changes due to apoptosis
were detected in Raji cells using CLSM. The Raji cells
were seeded in a 6-well plate (4 × 105 per well) and
incubated with PBS buffer, MSNs (50 μg/mL), Free
DOX, DMSNs and RDMSNs containing a DOX con-
centration of 2.0 μg/mL for 24 h. Next, the cells were
rinsed with cold PBS buffer three times and fixed with
4% paraformaldehyde at room temperature for 30 min.
Then, the samples were washed with PBS and stained
with DAPI (20 μg/mL) in NEST glass culture dishes for
30 min. Finally, the stained Raji cells were observed
under CLSM.
The cell apoptosis assay was analyzed by FCM with a
commercial Annexin V-FITC detection kit. The Raji
cells were treated using the same method. In addition,
the Raji cells were incubated with different concentra-
tions of RDMSNs (i.e., 0, 10, 20, 30, and 50 μg/mL).
After incubation for 24 h, the Raji cells were rinsed twice
with cold PBS buffer, resuspended in 195 μl of binding
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buffer solution and stained with 5 μl of FITC-labeled
Annexin V and 10 μl of PI for 15–20 min at room
temperature in the dark. Raji cells incubated in PBS
buffer were considered the control group.
RMSNs biological safety study in vivo
Female Babl/c mice were treated with RMSNs by tail
vein injection (100 μL, 100 mg/kg) one dose every 3 days
for 3 weeks. The nude mice treated with saline were
used as controls (3 mice per group). The body weight
was monitored every week. The main organs including
the heart, liver, spleen, lungs and kidneys were acquired
after the final treatment followed by Hematoxylin and
eosin (H&E) staining to detect the toxicity in vivo.
DOX distribution in tumors
Lymphoma model were established by subcutaneous in-
jection with 6 × 107 Raji cells into the right axillary space
of mice. When lymphoma volume reached approxi-
mately 100 mm3, the intravenous injection of Free DOX,
DMSNs and RDMSNs was then carried out at the DOX
dose of 2 mg / kg at 1, 6, and 24 h, respectively (9 mice
per group). After the sacrifice of 3 mice per group for
each time points, the tumors were excised and homoge-
nized with RIPA buffer. Subsequently, the supernatant
was collected by centrifugation and quantified for
DOX content by fluorimetry and normalized with the
tumor weight.
In vivo antitumor efficacy
Raji lymphoma bearing mice were established as de-
scribed above. When lymphoma volume reached ap-
proximately 100 mm3, Raji lymphoma bearing mice
were randomly divided into 4 groups (5 mice per group),
respectively : saline group, Free DOX group, DMSNs
group and RDMSNs group. Each Raji lymphoma bearing
mouse was treated with DOX related formulations (the
dose was 2 mg / kg) once every 4 days for a total four
times. The lymphoma sizes of all mice were monitored
by a digital caliper and calculated by the equation: Vtu-
mor = LW
2/2 (L: tumor length, W: tumor width). The
lymphoma volume and body weight were determined
every other day. After 16 days of treatment, all the mice
were sacrificed and the lymphoma were extracted and
fixed with 4% paraformaldehyde. Additionally, To detect
cell apoptosis in lymphoma tissue, lymphoma tissue was
sliced into thin sections and stained with a TUNEL
apoptosis detection kit. Next, the sample was stained
with DAPI solution to visualize cell nuclei under a fluor-
escence microscope.
Statistical analysis
All experiments were performed in triplicate. Results were
presented as mean ± standard deviation and analyzed
using SPSS 16.0 software (SPSS, Chicago, IL, USA).
Statistical analysis was carried out using a student’s t-test.
P < 0.05 was determined to be statistically significant.
Results
Preparation and characterization of nanoparticles
Scheme 1 shows the synthesis of DMSNs and RDMSNs.
RDMSNs were internalized by Raji cells via CD20
antigen-mediated endocytosis and then DOX was re-
leased into tumor cells by a pH trigger, which enhanced
intracellular drug accumulation. The size distribution
of the MSN-COOH was uniform and regular (Fig. 1a),
and the MSN-COOH possessed well-defined global
morphology (Fig. 1b). Furthermore, based on the FTIR
spectra, MSN-COOH exhibited an absorption peak at
1647–1720 cm−1, which characteristic of the C = O
stretching vibrations of carboxyl groups (Fig. 1c). The
mean diameter of MSN-COOH was in the range of
40.7 ± 19.1 nm. The zeta potential of MSN-COOH was
−32.6 ± 5.7 mV (Fig. 1d). These results indicated that
MSNs can serve as drug delivery carriers.
Characterization of nanoparticles drug loading and
release
To investigate the drug loading behavior of MSNs, an
anticancer drug (i.e., DOX) was chosen as a model drug.
The properties of the MSNs as a drug delivery system
were estimated by the DOX loading and encapsulation
efficiencies. The encapsulation efficiency was approxi-
mately 45.2 ± 3.1%, and the loading efficiency was ap-
proximately 23.5 ± 1.3%. The data are similar to that of
the previous study [35]. These results demonstrated that
the MSNs possessed a large storage space for the effect-
ive loading of DOX.
Size distribution and zeta potential of RDMSNs were
56.3 ± 11.2 nm and −31.5 ± 5.2 mV, respectively, and
there were no significant change compared to the MSNs,
indicating that the DOX payload in MSN-COOH as well
as the conjugation of rituximab on the surface of the
MSNs slightly altered the particle size and surface
charge of the MSNs (Table 1). To investigate the pH-
responsive drug release property, a release assay of
DMSNs and RDMSNs was carried out under pH 7.4,
pH 5.0 conditions in vitro. Only a DOX loading of 24.8
± 6.4 and 23.7 ± 5.1% was released from the DMSNs and
RDMSNs, respectively, at a pH of 7.4. However, a DOX
loading of approximately 76.4 ± 7.2 and 73.6 ± 6.2% was
released from the DMSNs and RDMSNs at a pH of 5.0,
respectively. The DOX released from nanoparticles was
significantly different at a pH of 5.0 compared with that
at a pH of 7.4 (Fig. 2). Additionally, the drug release
properties of DMSNs and RDMSNs in medium were
also estimated and the results were similar to those at a
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pH of 7.4 condition. Therefore, this drug delivery system
possessed pH-responsive drug release property.
The mesoporous structure of the MSN was further con-
firmed by the nitrogen adsorption/desorption isotherm.
The MSNs have well-defined mesoporous nanopores with
a surface area of 820 m2/g (Fig. 3a), a pore volume of
0.62 cm3/g and an average diameter of 2.5 nm (Fig. 3b).
After carboxyl grafting and cargo loading, the pore
volume and pore diameter of nanoparticles decreased,
indicating that the nanopores were blocked by the
incorporated DOX and rituximab molecules.
Subsequently, to estimate the rituximab conjugation
efficiency, the quantities of rituximab on the surface of
the RDMSNs were determined by examining the fluor-
escence intensity of the RDMSN suspensions. Fluores-
cence imaging of the RDMSNs revealed a dense layer of
green under CLSM, which confirmed the conjugation
of DyLight 488-labeled avidin onto the surface of the
RDMSNs (Fig. 4a). The fluorescence intensity of the
RDMSN suspensions was 66.25% for the DyLight 488-
labeled avidin samples, demonstrating the desired
conjugation efficiency of DyLight 488-labeled avidin to
the biotinylated DMSNs (Fig. 4b). Due to the high affin-
ity of avidin to biotin, we indirectly deduced the same
high linkage of biotinylated rituximab to the avidin-
conjugated RDMSNs. Therefore, the results showed that
the multifunctional MSNs could serve as a targeted drug
delivery system for B cell lymphoma therapy.
Cell recognition and internalization of DMSNs and
RDMSNs
To evaluate the tumor cell targetability of RDMSNs in
vitro, the amount of cellular internalization of DMSNs
and RDMSNs was analyzed using FCM. The MFI values
of the Raji cells treated with RDMSNs and DMSNs at
Table 1 Characterization of the MSNs
Groups Size distribution (nm) Zeta potential (mV)
MSN-COOH 40.7 ± 19.1 −32.6 ± 5.7
DMSNs 45.3 ± 17.6 −27.1 ± 3.8
RDMSNs 56.3 ± 11.2 −31.5 ± 5.2
All data were recorded by dynamic light scattering. Values are
means ± SD (n = 3)
Fig. 1 Representative characterizations of MSN and MSN-COOH. SEM images of MSN-COOH, scale bar: 500 nm (a), TEM images of MSN-COOH,
scale bar: 50 nm (b), the FT-IR spectra of MSN and MSN-COOH (c), and the zeta potential of MSN-COOH (d)
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37 °C for 2 h were 1445 and 543, respectively (Fig. 5a).
Moreover, the cellular recognition and internalization
behavior of DMSNs and RDMSNs were investigated
using CLSM in Raji and Jurkat cells, respectively. The
Raji cells that were incubated with RDMSNs exhibited
strong DOX fluorescence in the cytoplasm. In contrast,
the DOX fluorescence that was observed in the cyto-
plasm of Raji cells incubated with DMSNs was very
weak. In the rituximab blockage experiment, the
resulting outcome was indicated by weak DOX fluores-
cence in the cytoplasm of Raji cells. In addition, only a
weak DOX fluorescence was observed in Jurkat cells
incubated with RDMSNs and DMSNs (Fig. 5b). Further-
more, we used TEM to investigate the distribution of
DMSNs and RDMSNs after endocytosis in vitro.
RDMSNs and DMSNs aggregated only in the cytoplasm
but did not penetrate into the nucleus. Importantly,
more RDMSNs were internalized by Raji cells compared
Fig. 3 The characterizations of nanoparticles. BET nitrogen adsorption /desorption isotherms (a), and BJH pore size distribution of MSN, MSN-COOH
and RDMSNs. After carboxyl grafting and cargo loading, the pore volume and pore diameter of nanoparticles decreased, indicating that the nanopores
were blocked by the incorporated DOX and rituximab molecules (b)
Fig. 2 pH-responsive release profiles of DOX from the DMSNs and RDMSNs in medium and PBS solution (pH 5.0 and pH 7.4) over 48 h,
respectively. These results indicated that the DOX released from nanoparticles was more at a pH of 5.0 than that at a pH of 7.4 or medium.
RDMSNs (PBS pH7.4) vs RDMSNs (PBS pH5.0) (a), DMSNs (PBS pH7.4) vs DMSNs (PBS pH5.0) (b), RDMSNs (PBS pH 5.0) vs RDMSNs (medium) (c), and
DMSNs (PBS pH 5.0) vs DMSNs (medium) (d). Data are presented as mean ± SD from three independent experiments. *, P < 0.05; **, p < 0.01
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to DMSNs. In the negative control, the number of endo-
cytosed RDMSNs by Jurkat cells was similar to that of
DMSNs (Fig. 5c). Thus, these outcomes hinted that this
targeted drug delivery system can significantly more be
recognized and internalized by lymphoma B cells com-
pared to nontargeted drug delivery system.
Cell viability study of DMSNs and RDMSNs
Next, To estimate the cytotoxicity of MSNs, RMSNs,
DMSNs and RDMSNs, a CCK-8 assay was performed to
quantify the cell viability of Raji, Daudi and Jurkat cells.
Figure 6a showed the cell viability of Raji cells after being
incubated with a series of concentrations of MSNs or
Fig. 4 The fluorescence characterizations of nanoparticles. Imaging of MSNs was performed by CLSM (100 × objective) the loaded DOX imaging
of the RDMSNs (red fluorescence), DyLight 488-avidin imaging of the RDMSNs (green fluorescence), merge imaging of RDMSNs a. The fluorescence
absorbance of the RDMSNs, DMSNs and free DyLight 488-avidin were measured to analyze the rituximab conjugation efficiency. The fluorescence
intensity of the RDMSN suspensions was 66.25% for the DyLight 488-labeled avidin samples, demonstrating the desired conjugation efficiency of
biotinylated rituximab to the avidin-conjugated RDMSNs b
Fig. 5 The recognition and internalization of the DMSNs and RDMSNs in Raji and Jurkat cells, respectively. FCM analysis denotes the mean
fluorescence intensity of DOX inside Raji treated with RDMSNs was much higher compared to that of Jurkat cells. Data are presented as mean ± SD
from three independent experiments. **, p < 0.01 (a). The Raji cells that were incubated with RDMSNs exhibited strong DOX fluorescence in the
cytoplasm. In contrast, the DOX fluorescence that was observed in the cytoplasm of Raji cells incubated with DMSNs was very weak. The cell nucleus
were stained with DAPI (blue) (b). TEM images showing the distribution of the RDMSNs within Raji was more compared to that of Jurkat cells.
Moreover, more RDMSNs were internalized by Raji cells compared to DMSNs (c)
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RMSNs for 24 h. The cell viability of Raji cells treated with
100 μg/mL of MSNs was as high as 90%. Moreover,
similar results were obtained for the Daudi and Jurkat
cells (Fig. 6b and c). These experimental data demonstrate
that MSNs and RMSNs exhibit good biocompatibility.
The cell viability of Raji cells that were treated with
RDMSNs, DMSNs and Free DOX was also determined in
this study. When incubated with Raji cells, both the Free
DOX and DMSNs exhibited lower antitumor activity
compared to that of RDMSNs at the same DOX concen-
tration. Although both Free DOX and DMSNs exhibited
dose-dependent toxicity to the Raji cells, Free DOX had
much stronger cytotoxicity compared to that of DMSNs
(Fig. 6d). Similar results were obtained for the Daudi
cells (Fig. 6e). Additionally, a Jurkat cell control group
was also investigated. Jurkat cells incubated with
RDMSNs and DMSNs exhibited lower cytotoxicity
compared to that of Free DOX (Fig. 6f ). The viability of
Jurkat cells of the RDMSN and DMSN groups exhibited
no significant difference. Moreover, all cells incubated
with RDMSNs, DMSNs and Free DOX exhibited a
DOX dose-dependent cytotoxicity at a series of DOX
concentrations ranging from 0.1 to 4.0 μg/mL. These
results confirm that the prepared RDMSNs exhibit a
significant selective cytotoxicity effect on CD20 antigen
overexpressed tumor cells and can reduce the side ef-
fects on normal or healthy cells.
Cell apoptosis study of DMSNs and RDMSNs
To investigate Raji cell apoptosis after treatment with
MSNs, DMSNs, RDMSNs and Free DOX for 24 h, the
morphologies of the nucleus associated with apoptosis
were observed using CLSM. The cell apoptosis analysis
was also investigated using FCM. The Raji cells that
were treated with MSNs demonstrated a similar elliptic
nuclear morphology with intact profiles. The Raji cells
that were treated with RDMSNs exhibited the most
significantly irregular cell nuclei morphology with
shrinkage features compared to those of Raji cells
treated with DMSNs and Free DOX (Fig. 7a). The late
apoptosis or necrosis of Raji cells treated with PBS,
MSNs, Free DOX, DMSNs and RDMSNs for 24 h was
3.03 ± 0.36, 3.94 ± 0.54,18.22 ± 1.15,10.09 ± 1.1 and 23.29
± 1.37%, respectively. From these experimental data, the
late apoptosis or necrosis of Raji cells that were incu-
bated with RDMSNs was significantly higher than those
Fig. 6 The cytotoxicity of different formulations in Raji, Daudi, and Jurkat cells. Cytotoxicity of MSNs and RMSNs on Raji cells (a), Daudi cells (b)
and Jurkat cells (c). The cell viability of Raji cells treated with 100 μg/mL of MSNs or RMSNs was as high as 90%, implying that MSNs and RMSNs
have good biocompatibility. Cytotoxicity of Free DOX, DMSNs and RDMSNs on Raji cells (d), Daudi cells (e) and Jurkat cells (f). Raji and Daudi cells
treated with RDMSNs exhibited higher cytotoxicity compared to that of Free DOX, while Jurkat cells treated with RDMSNs exhibited lower
cytotoxicity compared to that of Free DOX at the same DOX concentration. Data are presented as mean ± SD from three independent
experiments.*, P < 0.05; **, p < 0.01
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of Raji cells incubated with DMSNs and Free DOX
(Fig. 7b). Moreover, we also detected the concentration-
dependent apoptosis efficiency caused by the RDMSNs.
After treatment for 24 h, Raji cell apoptosis increased
when the concentration of the RDMSNs increased
(Fig. 7c). These findings demonstrated that this targeted
drug delivery system could induce lymphoma B cells
apoptosis.
RMSNs biological safety study in vivo
The potential in vivo toxicity of MSNs for drug delivery
system is always of great concern. For safety purpose, we
evaluated the in vivo toxicity of the drug carrier in nude
mice treated with RMSNs by tail vein injection. We
completed the histological analyses, which indicated no
significant pathological lesions or damages in the major
organs from nude mice that were treated with RMSNs
for 3 weeks (Fig. 8a). Additionally, the increase in body
weight of the RMSNs and saline groups showed a similar
tendency over the 3 weeks (Fig. 8b). These results
demonstrated that RMSNs had a good biocompatibility.
Enhanced DOX accumulation in tumors and antitumor
efficacy in vivo
To investigate RDMSNs targeting capacity in vivo, the
content of DOX in tumor was examined at 1, 6, and 24 h
post injection in Raji cells grafted mice. As depicted in
Fig. 9a, the DOX distribution of tumors in all groups was
slowly reduced with time extending from 1 to 24 h post
injection. In spite of this declining tendency, it was
Fig. 7 Raji cells apoptosis characterizations in vitro. Nuclei morphologic characterizations of Raji cells after different treatment for 24 h at 37 °C
under CLSM (1000×, DAPI). The Raji cells that were treated with RDMSNs exhibited the most significantly irregular cell nuclei morphology with
shrinkage features compared to those of other groups. Note: Red arrows direct characteristic variations of nucleus (a). Apoptotic rate of Raji cells
treated for 24 h at 37 °C by FCM. The apoptosis efficiency of Raji cells that were incubated with RDMSNs was significantly higher than those of
other groups (b). Quantitative apoptosis analysis of Raji cells treated with various concentrations of RDMSNs for 24 h at 37 °C. *P < 0.05.
The concentration-dependent apoptosis efficiency was detected (c). Data are presented as mean ± SD from three independent experiments.*,
P < 0.05; **, p < 0.01
Fig. 8 In vivo biological safety study. H&E staining of major organs obtained from nude mice treated with saline and RMSNs for 3 weeks,
respectively. There was no significant pathological lesions or damages in the major organs from nude mice that were treated with RMSNs. Scale
bar: 100 μm (a). Body weight of nude mice after treatment with saline and RMSNs showed a gradually increased tendency, implying that RMSNs
had a good biocompatibility (n = 3) (b)
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observed that RDMSNs and DMSNs displayed much
higher DOX accumulation at each time point than Free
DOX. Importantly, RDMSNs exhibited obviously im-
proved content of DOX in tumor compared to that of
DMSNs, implying that the potent in vivo tumor targeting
of RDMSNs might be caused by the special binding of
antibodies and antigens of cell membrane.
To detect the therapeutic efficacy of RDMSNs, we
intravenously injected mice bearing lymphoma with
RDMSNs once every 4 days for 4 times. RDMSNs indi-
cated the strongest antitumor efficacy among all groups.
Furthermore, the tumor growth inhibition of DMSNs
group was higher than those of Free DOX group. Inter-
estingly, unlike the results of the cytotoxic effects evalu-
ation in vitro, Free DOX indicated a slight inhibition
effect on tumor growth in vivo. More importantly,
RDMSNs group showed stronger antitumor efficacy
compared to that of DMSNs group (Fig. 9b). After the
last injection, the average tumor volume of RDMSNs
group was much smaller than that of other groups,
which was further demonstrated through visual observa-
tion (Fig. 9d). Alteration of body weight is an indication
of systemic toxicity. To explore the potential systemic
toxicity of RDMSNs in vivo, the body weight of nude
mice was also periodically monitored. The mice weights
in Free DOX groups showed a continuous and slow re-
duction from the 8th day, indicating that DOX had se-
vere systemic toxicity on nude mice. However, the mice
weight increased gradually with different degrees after
injections of saline, DMSNs, and RDMSNs, respectively,
which could be attributed to the low toxicity of DOX at
injection dosage (Fig. 9c). Additionally, to detect the po-
tential mechanism of lymphoma growth inhibition by
this drug delivery system, TUNEL apoptosis assay was
carried out to evaluate the antitumor efficacy. Sparse cell
apoptosis (green fluorescence) was observed in groups
treated with saline. The lymphoma tissues of mice
treated with DMSNs and Free DOX displayed moderate
cell apoptosis (green fluorescence), while those treated
with RDMSNs exhibited the most significant apoptosis
among all groups (Fig. 10). These results firmly verified
that RDMSNs could inhibit tumor growth via inducing
cells apoptosis in lymphoma. Therefore, RDMSNs could
be used to reduce the nonspecific toxicity of DOX
and realize the clinical application of some potent anti-
tumor agents.
Discussion
In the war against lymphoma, chemotherapy is presently
the most common treatment. However, its efficiency is
hampered by severe toxic side effects. These adverse
effects often lead to a drug dose reduction or discontinu-
ation of treatments in clinical applications. Nanoparticles
as excellent drug delivery carriers have been reported to
serve as an effective approach to enhance the drug efficacy
and reduce adverse effects [36, 37]. The drug-loaded
MSNs have been reported to serve as a promising drug
carrier for all types of solid tumors therapy. However, the
ligands conjugated to targeted drug-loaded MSNs had the
unwanted immunogenicity. In this study, we successfully
designed and constructed an intracellular pH-responsive
and targeted drug delivery system based on DOX-loaded
MSNs to enhance the therapeutic index and reduce the
side effects of B cell lymphoma therapy.
The prepared RDMSNs have several advantages. First,
PEG as a polymer protective layer could suppress plasma
Fig. 9 In vivo tumorous distribution and therapeutic effect of RDMSNs. The content of DOX in tumors treated with RDMSNs was much higher
compared with those of other groups at different time points (n = 3). *P < 0.05,** P < 0.01 vs RDMSNs (a). Tumors treated with RDMSNs grew
slowly compared to those of other groups. From the 10th day, the mean tumor volume of mice treated with RDMSNs was significantly different
compared with those of other groups (b). The mice weight increased gradually with different degrees after injections of saline, DMSNs, and
RDMSNs, respectively, while the mice weight in Free DOX groups showed a gentle reduction from the 8th day, indicating that Free DOX
had severe systemic toxicity on nude mice. From the 10th day, the mean body weight of mice treated with Free DOX was significantly
different compared with those of other groups (c). After 16 days culture, the volumes of tumors treated with saline were significantly
larger compared to those of other groups. In contrast, The mice treated with RDMSNs exhibited significant inhibition of tumor growth in
volume (d) (n = 5,*P < 0.05,** P < 0.01)
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protein adsorption. Furthermore, rituximab as tumor-
targeting components could carry out CD20 antigen-
mediated cell internationalization. Additionally, DOX-
loaded RDMSNs could be released by a low pH signal at
the targeted site. Thus, after the multifunctional RDMSNs
reach their targeted sites, the rituximab on the outer layer
can specifically adhere to the CD20 antigen on the mem-
branes of lymphoma B cells, leading to receptor-mediated
cell pinocytosis or endocytosis and endosome or lysosome
formation inside the tumor cells. Then, the loaded drug can
be rapidly released from the multifunctional RDMSNs due
to a reduction of the electrostatic interaction triggered by
the lower pH of the acidic environment of the endosome or
lysosome. Therefore, these multifunctional RDMSNs have
the potential for use as an intracellular pH-responsive and
targeted drug delivery system for B cell lymphoma therapy.
In this study, the zeta potential results demonstrated
that the MSNs were negatively charged at a pH of 7.4
due to the large amount of negatively charged silanol
group on the MSNs, which is consistent with that re-
ported in a previous study [38]. Moreover, several stud-
ies confirmed that the isoelectric point (pI) of DOX is
8.2. It is important to note that the pI values of DOX
are higher than pH 7.4, revealing that the DOX mole-
cules are positively charged in the physiological micro-
environment. Therefore, the DOX molecule can fill the
mesoporous channels of the MSNs under pH 7.4 condi-
tions via electrostatic interactions between the negative
charges of the MSNs and the positive charges of the
DOX molecules. Thus, the DMSNs further exhibit high
loading and encapsulation efficiencies. In the drug re-
lease assay, no significant difference in the amount of re-
leased DOX was observed between the DMSNs and
RDMSNs at the same pH value. Furthermore, the conju-
gation of rituximab did not influence the release of DOX
at the different pH values. Interestingly, the release
efficiency of DOX at a pH of 5.5 was higher than that at
pH of 7.4 or in medium, indicating that a lower pH value
was more beneficial to DOX release from the DMSNs or
RDMSNs. These results were supported by those from
previous studies [39]. The pH-responsive DOX release
was due to the weakly electrostatic attraction at acidic pH
and the strongly electrostatic attraction at physiological
pH between MSNs and DOX molecules. Due to this
property, the pH-responsive and targeted drug release
system could effectively decrease DOX release during
blood circulation (pH 7.4) and improve DOX release in
the endosomes or lysosomes (pH 4.5–5.5) of tumor cells.
Therefore, reduced DOX side effects and enhanced
intracellular DOX accumulation could be achieved via this
pH-responsive and targeted drug delivery system.
Previous studies reported similar results whereby a tar-
geted modification of ligand enhanced the internalization
and cytotoxicity effect of nanoparticles via the receptor-
mediated endocytosis pathway [40–42]. In our study, the re-
sults demonstrated that more RDMSNs were recognized
and internalized by CD20 antigen positive Raji cells com-
pared to DMSNs. Furthermore, the prepared RDMSNs ex-
hibited higher cytotoxicity effect and apoptosis efficiency
compared to those of Free DOX and DMSNs at the same
DOX concentration in the CD20 antigen positive Raji cells.
Also, Raji cell apoptosis increased when the concentration
of the RDMSNs increased. These should be the covalent
conjugations of Rituximab as a ligand which provide active
targeting and improved endocytosis of RDMSNs by lymph-
oma B cells by overexpressing CD20 antigen, enhancing
Fig. 10 TUNEL assays showed that tumors treated with RDMSNs exhibited significantly more apoptosis DNA compared to those of other groups.
Histological apoptosis observation in tumor tissues by TUNEL staining after the tumor-bearing mice were treated with Saline, Free DOX, DMSNs,
and RDMSNs for 16 days, respectively. Green: apoptosis DNA; Blue: cell nuclei. Scale bar: 50 μm
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drug efficacy and promoting lymphoma B cells death. In this
research in vivo, Free DOX only exhibited a moderate
inhibition effect on lymphoma growth compared to that of
DMSNs, which was different from the results of cell viability
evaluation in vitro. It was attributed to the fact that Free
DOX rapidly diffused into all tissues of mice after intraven-
ous administration, leading to potential toxic side effect on
healthy tissues, thus only small amount of DOX molecule
could reach tumor sites in vivo. On the other hand, Free
DOX has shorter half life in vivo, and would be eliminated
during the blood circulation and metabolism. Additionally,
the enhanced antitumor activity, increased cell apoptosis
observed via TUNEL staining assay and reduced systemic
toxicity of RDMSNs could probably be involved in the
following factors: (1) DOX molecule loaded into the hole of
MSNs effectively protected it from quick clearance during
blood circulation; (2) Enhanced permeability and retention
effect of stealth RDMSNs would passively and actively ag-
gregate the RDMSNs at the tumor site; (3) CD20 antigen-
mediated cell specific endocytosis or internalization of the
RDMSNs were occurred via CD20 antigen positive Raji
cells, improving cell uptake of RDMSNs, and promoting the
local chemotherapeutics accumulation. (4) Due to the pH-
responsive property, the intracellular DOX release of
RDMSNs was improved in the endosomes or lysosomes
(pH 4.5–5.5) of tumor cells. (5) The enhanced antitumor
efficacy of RDMSNs was occurred through inducing lymph-
oma cells apoptosis. (6) Rituximab as a molecular targeted
drug can induce the antibody-dependent cell-mediated
cytotoxicity and complement dependent cytotoxicity. Thus,
the synergistic effect of the DOX and Rituximab in the
RDMSNs resulted in excellent tumor inhibition effect. (7)
DOX is an anthraquinone anticancer agent that is com-
monly used for the treatment of various types of tumors.
DOX can specifically inhibit topoisomeraseIIenzyme activ-
ity. However, topoisomeraseIIplays an important role in
DNA replication [43]. All these results demonstrated that
RDMSNs exhibited both the excellent antitumor effect and
the reduced systemic toxicity. Taken together, our study
displayed that RDMSNs could serve as an effective and safe
platform to improve the therapeutic effect of antitumor
drugs and reduce the associated side effects.
Conclusions
In summary, we have designed and constructed a targeted
and DOX-loaded drug delivery system based on MSNs
with CD20 antigen-mediated cancer cell uptake and intra-
cellular pH-responsive controlled drug release features.
More DOX can be released in an acidic environment
(pH 5.0) than in a neutral environment (pH 7.4). The in
vitro experiments demonstrated that RDMSNs exhibited
targeting accumulation and improved the cytotoxic effects
on CD20 positive lymphoma B cells. Furthermore, the in
vivo investigations confirmed that RDMSNs could
efficiently deliver DOX to tumor cells by pH stimuli, thus
inducing cell apoptosis and inhibiting tumor growth, while
with minimal toxic side effects. These results suggest that
this targeted drug delivery system has the potential for
applications in B cell lymphoma therapy.
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